A Molecular Subtype–Specific Stochastic Simulation Model of US Breast Cancer Incidence,Survival,and Mortality Trends from 1975 to 2010

Abstract

We present a Monte Carlo simulation model that reproduces US invasive breast cancer incidence and mortality trends from 1975 to 2010 as a function of screening and adjuvant treatment. This model was developed for multiple purposes, including to quantify the impact of screening and adjuvant therapy on past and current trends, predict future trends, and evaluate potential outcomes under hypothetical screening and treatment interventions. The model first generates the life histories of individual breast cancer patients by determining the patient’s age, tumor size, estrogen receptor (ER) status, human epidermal growth factor 2 (HER2) status, SEER (Surveillance, Epidemiology, and End Results) historic stage, detection mode at time of detection, preclinical tumor course, and death age and cause of death (breast cancer v. other causes). The model incorporates common inputs used by the Cancer Intervention and Surveillance Modeling Network (CISNET), including the dissemination patterns for screening mammography, breast cancer survival in the absence of adjuvant therapy, dissemination and efficacy of treatment by ER and HER2 status, and death from causes other than breast cancer. In this article, predicted mortality outcomes are compared assuming proportional v. nonproportional hazards effects of treatment on breast cancer survival. We found that the proportional hazards treatment effects are sufficient for ER-negative disease. However, for ER-positive disease, the treatment effects appear to be higher during the early years following diagnosis and then diminish over time. Using nonproportional hazards effects for ER-positive cases, the predicted breast cancer mortality rates closely match the SEER mortality trends from 1975 to 2010, particularly after 1995. Our work indicates that population-level simulation modeling may have a broader role in assessing the time dependence of treatment effects.

Keywords

breast cancer incidence trends breast cancer mortality trends nonproportional hazards SEER time-dependent treatment effects

Get full access to this article

View all access options for this article.

References

Berry

Cronin

Plevritis

et al . Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92.

Piccart-Gebhart

Procter

Leyland-Jones

et al . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.

Romond

Perez

Bryant

et al . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

Slamon

Eiermann

Robert

et al . Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

Dowsett

Cuzick

Ingle

et al . Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.

Yin

Jiang

Shen

Shao

. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One. 2011;6(6):e21030.

Slamon

Leyland-Jones Shak

et al . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.

10.

Cox

. Regression models and life-tables. J Royal Stat Soc. Series B (Methodol). 1972;34(2):187–220.

11.

Jeong

Jung

Wieand

. A parametric model for long-term follow-up data from phase III breast cancer clinical trials. Stat Med. 2003;22(3):339–52.

12.

Berry

Cirrincione

Henderson

et al . Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295(14):1658–67.

13.

Dignam

Dukic

Anderson

Mamounas

Wickerham

Wolmark

. Hazard of recurrence and adjuvant treatment effects over time in lymph node–negative breast cancer. Breast Cancer Res Treat. 2009;116(3):595–602.

14.

Jatoi

Bandos

Jeong

et al . Time-varying effects of breast cancer adjuvant systemic therapy. J Natl Cancer Inst. 2016;108(1):djv304.

15.

Plevritis

Sigal

Salzman

Rosenberg

Glynn

. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr. 2006;(36):86–95.

16.

Mandelblatt

Near

Miglioretti

et al . Common model inputs in collaborative breast cancer modeling. Medical Decis Making. 2018;38(1S):9–23.

17.

Jackson

Vanness

Stout

et al . Contribution of breast cancer to overall mortality for U.S. women. Medical Decis Making. 2018;38(1S):24–31.

18.

Holford

. The estimation of age, period and cohort effects for vital rates. Biometrics. 1983;39(2):311–24.

19.

Holford

Cronin

Mariotto

Feuer

. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006;(36):19–25.

20.

Munoz

Plevritis

. Understanding the temporal trends in breast cancer incidence in the United States: a novel approach to address identifiability in age-period-cohort models. Manuscript in preparation.

21.

Munoz

Plevritis

. Estimating breast cancer survival by molecular subtype in the absence of screening and treatment. Under review for publication.

22.

Alagoz

Berry

de Koning

et al . Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) breast cancer models. Med Decis Making. 2018;38(1S):3–8.

23.

Burstein

Temin

Anderson

et al . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–2269.